Protagonist Therapeutics Inc (PTGX) — Capital Reinvestment Ratio

Latest as of March 2025: 0.00x

Protagonist Therapeutics Inc (PTGX) has a Capital Reinvestment Ratio of 0.00x as of March 2025, meaning it reinvests 0% of its operating cash flow ($125.36 Million) in capital expenditures ($545.00K). See Protagonist Therapeutics Inc (PTGX) net asset quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$125.36 Million
USD

Capital Expenditures

$545.00K
USD

Data as of

Mar 2025
Most recent filing

Protagonist Therapeutics Inc Capital Reinvestment Ratio (2017–2024)

This chart tracks Protagonist Therapeutics Inc's Capital Reinvestment Ratio across 2 annual periods. Check Protagonist Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Protagonist Therapeutics Inc (2017–2024)

Year-by-year Capital Reinvestment Ratio for Protagonist Therapeutics Inc from 2017 to 2024. For live market cap and broader valuation context, see Protagonist Therapeutics Inc market cap and net worth.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2024 0.01x $184.15 Million $1.35 Million ▼ -95.7%
2017 0.17x $3.87 Million $666.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow